P-glycoprotein mediates resistance to A3 adenosine receptor agonist 2-chloro-N 6-(3-iodobenzyl)-adenosine-5'-n-methyluronamide in human leukemia cells

Journal of Cellular Physiology

Volumn 227, Issue 2, 2012, Pages 676-685

  Mlejnek, Petr ^a   Dolezel, Petr ^a   Kosztyu, Petr ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLURONAMIDE; 6 ETHYL 2 PHENYL 4 PROPYL 3 PYRIDINECARBOXYLIC ACID 5 THIOCARBOXYLIC ACID 5 ETHYL 3 PROPYL ESTER; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; FAS LIGAND; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VALSPODAR;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ASSAY; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOSINE; ADENOSINE A3 RECEPTOR AGONISTS; ADENOSINE TRIPHOSPHATASES; CELL DEATH; CELL LINE, TUMOR; CELL MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA; P-GLYCOPROTEIN; RECEPTOR, ADENOSINE A3;

EID: 82155188526     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22775     Document Type: Article

References (38)

1. Abbracchio MP, Burnstock G. 1998. Purinergic signalling: Pathophysiological roles. Jpn J Pharmacol 78: 113-145.
2. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. 1999. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398.
3. Boesch D, Muller K, Pourtier-Manzanedo A, Loor F. 1997. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res 196: 26-32.
4. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
5. Chen Y, Pant AC, Simon SM. 2001. P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells. Cancer Res 61: 7763-7769.
6. Dean M, Hamon Y, Allikmets R. 2001. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11: 1156-1166.
7. Dolezel P, Koudelkova P, Mlejnek P. 2010. Halogenation of N6-benzyladenosine decreases its cytotoxicity in human leukemia cells. Toxicol In Vitro 24: 2079-2083.
8. Endicott JA, Ling V. 1989. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171.
9. Fishman P, Madi L, Bar-Yehuda S, Barer F, Del Valle L, Khalili K. 2000. Adenosine acts as an inhibitor of lymphoma cell growth: A major role for the A3 adenosine receptor. Eur J Cancer 36: 1452-1458.
10. Fishman P, Bar-Yehuda S, Madi L, Cohn I. 2002a. A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs 13: 437-443.
11. Fishman P, Madi L, Bar-Yehuda S, Barer F, Del Valle L, Khalili K. 2002b. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene 21: 4060-4064.
12. Fojo T, Bates S. 2003. Strategies for reversing drug resistance. Oncogene 22: 7512-7523.
13. Fojo A, Akiyama S, Gottesman MM, Pastan I. 1985. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res 45: 3002-3007.
14. Frydrych I, Mlejnek P. 2008. Serine protease inhibitors N-α-tosyl-L-lysinyl-chloromethylketone (TLCK) and N-tosyl-L-phenylalaninyl-chloromethylketone (TPCK) are potent inhibitors of activated caspase proteases. J Cell Biochem 103: 1646-1656.
15. Gao Z, Li BS, Day YJ, Linden J. 2001. A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol Pharmacol 59: 76-82.
16. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA. 2008. The A3 adenosine receptor: An enigmatic player in cell biology. Pharmacol Ther 117: 123-140.
17. Gottesman MM, Pastan I. 1993. Biochemistry of multigrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427.
18. Gottesman MM, Fojo T, Bates SE. 2002. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
19. Jacobson KA. 1998. Adenosine A3 receptors: Novel ligands and paradoxical effects. Trends Pharmacol Sci 19: 184-191.
20. Juliano RV, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162.
21. Katewa SD, Katyare SS. 2003. A simplified method for inorganic phosphate determination and its application for phosphate analysis in enzyme assays. Anal Biochem 323: 180-187.
22. Kim SG, Ravi G, Hoffmann C, Jung YJ, Kim M, Chen A, Jacobson KA. 2002. P53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA. Biochem Pharmacol 63: 871-880.
23. Kohno Y, Sei Y, Koshiba M, Kim HO, Jacobson KA. 1996. Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists. Biochem Biophys Res Commun 219: 904-910.
24. Ludescher C, Thaler J, Drach D, Drach J, Spitaler M, Gattringer C, Huber H, Hofmann J. 1992. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br J Haematol 82: 161-168.
25. Madi L, Ochaion A, Rath-Wolfson L, Bar-Yehuda S, Erlanger A, Ohana G, Harish A, Merimski O, Barer F, Fishman P. 2004. The A3 adenosine receptor is highly expressed in tumor versus normal cells: Potential target for tumor growth inhibition. Clin Cancer Res 10: 4472-4479.
26. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA, Borea PA. 2003. A glance at adenosine receptors: Novel target for antitumor therapy. Pharmacol Ther 100: 31-48.
27. Mlejnek P, Dolezel P. 2010. Induction of apoptosis by A3 adenosine receptor agonist N6-(3-iodobenzyl)-adenosine-5'-N-methylcarboxamide in human leukemia cells: A possible involvement of intracellular mechanism. Acta Physiol 199: 171-179.
28. Mlejnek P, Dolezel P, Faber E, Kosztyu P. In press. Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells. Ann Hematol. (Accepted for publication).
29. Morello S, Sorrentino R, Porta A, Forte G, Popolo A, Petrella A, Pinto A. 2009. CI-IB-MECA Enhances TRAIL-induced apoptosis via the modulation of NF-kappa B signalling pathway in thyroid cancer cells. J Cell Physiol 221: 378-386.
30. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
31. Ohana G, Bar-Yehuda S, Barer F, Fishman P. 2001. Differential effect of adenosine on tumor and normal cell growth: Focus on the A3 adenosine receptor. J Cell Physiol 186: 19-23.
32. Omote H, Al-Shawi MK. 2006. Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism. Biophys J 90: 4046-4059.
33. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS. 1996. Inhibition of TNF-alpha expression by adenosine: Role of A3 adenosine receptors. J Immunol 156: 3435-3442.
34. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. 1992. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 267: 4854-4858.
35. Shneyvays V, Jacobson KA, Li AH, Nawrath H, Zinman T, Isaac A, Shainberg A. 2000. Induction of apoptosis in rat cardiocytes by A3 adenosine receptor activation and its suppression by isoproterenol. Exp Cell Res 257: 111-126.
36. Shneyvays V, Mamedova L, Zinman T, Jacobson K, Shainberg A. 2001. Activation of A(3)adenosine receptor protects against doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 33: 1249-1261.
37. Silva J, Chang K, Hannon GJ, Rivas FV. 2004. RNA-interference-based functional genomics in mammalian cells: Reverse genetics coming of age. Oncogene 23: 8401-8409.
38. Tang R, Faussat AM, Perrot JY, Marjanovic Z, Cohen S, Storme T, Morjani H, Legrand O, Marie JP. 2008. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer 8: 51-59.